NOSIP

NOSIP is a nucleocytoplasmic shuttling protein and ubiquitin E3 ligase that couples nitric oxide synthase regulation, phosphatase control, and vertebrate neurodevelopment (PMID:11149895, PMID:25546391, PMID:28663132). It binds directly to the carboxyl-terminal region of the eNOS oxygenase domain, a contact antagonized by the caveolin-1 scaffolding domain, and upon overexpression drives eNOS out of plasma membrane caveolae into intracellular compartments to suppress NO production (PMID:11149895). Endogenous NOSIP executes this regulation in a cell-cycle-restricted manner, targeting eNOS to the actin cytoskeleton specifically in G2 phase to inhibit its enzymatic activity (PMID:16135813). Its localization is governed by a bipartite NLS that mediates importin-alpha-dependent nuclear import and a CRM1-independent export pathway, with G2-phase cytoplasmic accumulation being required for cytoskeletal targeting of eNOS (PMID:16135813). Independently, NOSIP acts as an E3 ligase that monoubiquitinates the PP2A catalytic subunit, and its loss elevates PP2A activity in vivo (PMID:25546391). NOSIP is essential for brain and craniofacial development: knockout mice develop holoprosencephaly and midline craniofacial defects, and NOSIP sustains neural progenitor self-renewal and neurogenesis by acting upstream of Rbp1 within a retinoic acid signalling pathway that also controls eye field induction and neural crest formation (PMID:25546391, PMID:28663132, PMID:30055071).

1. 2001 High

   Established the molecular identity of NOSIP as a direct eNOS partner and defined where it binds, answering whether a dedicated protein regulates eNOS independently of caveolin.

   Evidence Yeast two-hybrid screen with reciprocal Co-IP in vitro and in vivo, plus caveolin-1 scaffolding-domain peptide competition

   PMID:11149895

   Open questions at the time

   • Did not define whether binding alters eNOS catalysis directly or only via relocalization
   • No structural model of the NOSIP-eNOS interface
2. 2001 High

   Showed that NOSIP functionally suppresses NO output by physically displacing eNOS from caveolae, linking binding to a downstream signalling consequence.

   Evidence Subcellular fractionation, detergent solubility, immunofluorescence, and NO assays in CHO-eNOS cells overexpressing NOSIP

   PMID:11149895

   Open questions at the time

   • Overexpression context may not reflect endogenous stoichiometry
   • Destination compartment of displaced eNOS not resolved at this stage
3. 2005 High

   Demonstrated that endogenous NOSIP regulates eNOS in a cell-cycle-specific window, revealing physiological timing and the actin cytoskeleton as the relocalization target.

   Evidence siRNA knockdown with cell-cycle synchronization, cytoskeletal association assay, and eNOS activity assay

   PMID:16135813

   Open questions at the time

   • Trigger that activates NOSIP-mediated targeting specifically in G2 not identified
   • Functional purpose of G2-restricted NO suppression unclear
4. 2005 High

   Explained the localization logic by defining NOSIP shuttling, showing nuclear import requires a bipartite NLS and importin alpha while export is CRM1-independent, and that cytoplasmic accumulation enables eNOS targeting.

   Evidence NLS mutagenesis, importin-alpha Co-IP, leptomycin B treatment, and cell-cycle immunofluorescence

   PMID:16135813

   Open questions at the time

   • Identity of the CRM1-independent export receptor unknown
   • Nuclear function of NOSIP not defined
5. 2002 Medium

   Extended the eNOS interaction beyond vascular cells, confirming physiological relevance in gastrointestinal tissue.

   Evidence Co-IP from rat small intestine lysate

   PMID:12105859

   Open questions at the time

   • Single Co-IP without functional readout in this tissue
   • No reciprocal pulldown reported
6. 2005 Medium

   Broadened the eNOS interaction to airway and lung tissue, supporting a general role in eNOS regulation across organs.

   Evidence Co-IP from rat lung, RT-PCR, immunohistochemistry

   PMID:15684328

   Open questions at the time

   • Functional consequence for lung NO signalling not tested
   • Single-tissue correlative localization
7. 2014 High

   Reframed NOSIP as an enzyme, establishing it as a ubiquitin E3 ligase that monoubiquitinates the PP2A catalytic subunit and restrains PP2A activity in vivo.

   Evidence In vitro monoubiquitination assay, MS-based interactome, and PP2A activity assay in NOSIP knockout craniofacial tissue

   PMID:25546391

   Open questions at the time

   • Catalytic domain/RING or HECT identity of NOSIP not specified
   • Functional outcome of PP2A monoubiquitination on substrate specificity unresolved
8. 2014 High

   Connected NOSIP loss to a defined developmental disease phenotype, establishing it as a modulator of brain and craniofacial morphogenesis.

   Evidence NOSIP knockout mouse generation and phenotypic analysis

   PMID:25546391

   Open questions at the time

   • Whether the phenotype derives from PP2A, eNOS, or another pathway not disentangled
   • Human disease correlate not established in this study
9. 2017 High

   Placed NOSIP in a defined neurogenic pathway, showing it sustains neural progenitor self-renewal and acts genetically upstream of Rbp1 in retinoic acid signalling.

   Evidence Knockout mouse neurosphere assay, MS proteomics, and Xenopus morpholino knockdown with human NOSIP rescue and Rbp1 epistasis

   PMID:28663132

   Open questions at the time

   • Direct biochemical link between NOSIP and Rbp1 not established
   • Whether E3 ligase activity is required for neurogenic function untested
10. 2018 Medium

    Extended the developmental role to eye and neural crest induction, reinforcing the link to retinoic acid signalling via foxc1.

    Evidence Xenopus morpholino knockdown with marker gene analysis, mouse conditional analysis, immunohistochemistry

    PMID:30055071

    Open questions at the time

    • Mechanistic step connecting NOSIP to retinoic acid output not defined
    • Single-lab loss-of-function data
11. 2021 Medium

    Implicated NOSIP in NO regulation during granulopoiesis, where its downregulation tracks with increased NO release via nNOS.

    Evidence nNOS overexpression in K562 cells, nNOS inhibitor treatment in mice and human CD34+ HSPCs, NOSIP expression analysis during differentiation

    PMID:33771575

    Open questions at the time

    • Direct NOSIP-nNOS interaction not demonstrated in this study; inferred from expression changes
    • Causality between NOSIP decrease and NO release not established by loss-of-function

• How NOSIP's two molecular activities — eNOS relocalization and PP2A monoubiquitination — mechanistically converge to drive retinoic-acid-dependent neurodevelopment remains unresolved.
• No defined catalytic domain or full substrate repertoire for the E3 ligase activity
• Unknown whether NO regulation and PP2A ubiquitination operate in the same developmental pathway
• Mechanism connecting NOSIP to Rbp1/retinoic acid signalling not biochemically defined